Department of Adult Hematology/Oncology, Indiana University School of Medicine, Indianapolis, United States.
Department of Pediatric Hematology/Oncology, Indiana University School of Medicine, Indianapolis, United States.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2048560. doi: 10.1080/21645515.2022.2048560. Epub 2022 Mar 28.
As of 05/28/2021, SARS-CoV-2 (COVID-19) had caused 3.9 million infections in the United States (US) pediatric population since its discovery in December of 2019. The development and expansion of vaccination has markedly changed the shape of the epidemic. In this qualitative study, we report on pediatric hematology/oncology provider views on the COVID-19 vaccine prior to approval in the adolescent population <16 years of age. Results from interviews with 20 providers across the state of Indiana showed that most were supportive of the COVID-19 vaccine for healthy adults. However, the majority also expressed a need to see more data on the safety and effectiveness of COVID-19 vaccinations in pediatric hematology/oncology populations. While they recognized the public health importance of vaccination, their duty to protect their patients led to a need for more specific safety and efficacy data.
截至 2021 年 5 月 28 日，自 2019 年 12 月发现以来，SARS-CoV-2（COVID-19）已导致美国儿科人群中 390 万人感染。疫苗的开发和推广显著改变了疫情的态势。在这项定性研究中，我们报告了在批准 16 岁以下青少年使用 COVID-19 疫苗之前，儿科血液学/肿瘤学提供者对 COVID-19 疫苗的看法。对印第安纳州 20 名提供者的访谈结果表明，大多数人支持 COVID-19 疫苗用于健康成年人。然而，大多数人也表示需要更多关于 COVID-19 疫苗在儿科血液学/肿瘤学人群中的安全性和有效性的数据。虽然他们认识到疫苗接种的公共卫生重要性，但他们保护患者的职责要求更具体的安全性和有效性数据。
